Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by
immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been
shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients …

Retinoic acid (RA), the major bioactive metabolite of retinol or vitamin A, induces a spectrum
of pleiotropic effects in cell growth and differentiation that are relevant for embryonic …

Historically, acute promyelocytic leukemia (APL) was considered to be one of the most fatal
forms of acute leukemia with poor outcomes before the introduction of the vitamin A …

The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO)
into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management …

Although acute promyelocytic leukemia (APL) is one of the most characterized forms of
acute myeloid leukemia (AML), the molecular mechanisms involved in the development and …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …